Tecentriq SC, launched in India by the pharma giant Roche, is subcutaneous. This means it is injected directly under the skin ...

Day One Biopharmaceuticals, Inc., now part of Servier Group, today announced that it has completed enrollment in the ...

Researchers compared outcomes of patients with colon cancer and hypertension taking RASIs in the first month after surgery ...

Treatments based on genomic profiling can significantly extend survival for patients with advanced or rare cancer, but only ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...

Every single type of cancer, explained A cancer diagnosis can be both terrifying and confusing for those afflicted, as well ...

Investigators analyzed the immune-modulatory cancer vaccine IO102-IO103 plus pembrolizumab for PFS in patients with untreated advanced melanoma.

When comprehensive tissue next-generation sequencing (NGS) fails, liquid biopsy should be the reflex strategy, especially in stage IV disease, where tissue-plasma concordance is h ...

Metastatic brain tumors (MBTs) represent the most common intracranial malignancy in adults, occurring approximately four to ten times more frequently than primary brain tumors. Despite advances in ...

India, April 26 -- A promising new drug for spinal tumors has recently received breakthrough therapy designation from the U.S. Food and Drug Administration. Plixorafenib, a novel, investigational ...

PDS Biotech has released data from the Phase II investigator-led colorectal cancer trial.

Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...